Authors
Latest:
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 StudiesExpert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.
Latest:
CheckMate 649 Study in GI Cancers Shows Survival Benefit for Nivolumab/ChemotherapyJaffer A. Ajani, MD, discusses the design and results of the CheckMate 649 study of nivolumab, ipilimumab, and chemotherapy for gastric cancers.
Latest:
Phase I/II Study Demonstrates Good Efficacy for Gastric CancerShuichi Hironaka, MD, PhD, discusses the efficacy of a phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line treatment of patients with advanced gastric cancer during the 2020 Gastrointestinal Cancers Symposium.
Latest:
Achieving Health Equity in Liver CancerPrimary liver cancer death rates vary by region, and much is still to be done in the area of health equity.
Latest:
Biomarkers Employed in CheckMate 739 for Patients With MPMSolange Peters, MD, PhD, discusses the biomarkers for immunotherapy used in the phase 3 CheckMate 743 trial.
Latest:
Best Therapies for HER2+ Breast Cancer Are Also Best for Brain MetastasesThomas Bachelot, MD, PhD, discusses therapies available for patients with HER2-positive breast cancer and brain metastases.
Latest:
Key Takeaways Regarding Biomarker Testing for mNSCLCClosing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.
Latest:
COVID-19 and Its Impact on Oncology Clinical TrialsCoronavirus disease 2019 has disrupted oncologic care across the spectrum of cancer screening, diagnosis, and management.
Latest:
Novel Combination Therapy Impresses With Safety/Efficacy in DLBCLChristopher J. Melani, MD, discusses updated data from the phase 1b/2 ViPOR trial of the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, in patients with diffuse large B-cell lymphoma.
Latest:
Low Receipt of ACR-Recommended Follow-Care Discovered Among Patients With Lung CancerAccording to a prospective study of lung cancer screening examinations conducted over a 5-year period, there is low adherence to guidelines recommending follow-up radiologic imaging or diagnostic procedures in patient with lung cancer.
Latest:
Treatment Approaches for Early-Stage Lung CancerPatrick Forde, MBBCh offers an overview of current standard-of-care treatments as well as emerging immunotherapy options for treating early-stage, resectable non-small cell lung cancer.
Latest:
Osimertinib Proves Frontline Status in EGFR+ Advanced NSCLCJonathan W. Goldman, MD, discusses the use of osimertinib in the first line setting for patients with non–small cell lung cancer.
Latest:
Underused Next-Generation Sequence Testing Revealed in MYLUNG Consortium StudyResults from the first phase of the broad, collaborative MYLUNG research study in lung cancer provide a close-up look at current biomarker testing rates and turnaround times for patients treated in community practices within The US Oncology Network.
Latest:
Closing Remarks on Bispecific AntibodiesJustin LaPorte, PharmD, BCOP, offers closing remarks following discussion on the administration of bispecific antibodies.
Latest:
Pancreatic Cancer Awareness Month: Novel Targeted Therapy in PDACThe landscape for patients with pancreatic ductal adenocarcinoma has shifted due to novel targeted therapies that are opening new options for patients.
Latest:
Methods and Design of the QUILT 3032 Study in NMIBCSam S. Chang, MD, MBA, discusses the methods and design of the QUILT 3032 study.
Latest:
First- and Later-Line Therapies in Patients With GISTDomenech Asbun, MD, discusses first-, second-, and later lines of therapy for patients with gastrointestinal stromal tumor.
Latest:
Important Biomarkers for Cervical and Ovarian CancersJohn Diaz, discusses key targets for cervical cancer and ovarian cancer.
Latest:
FDA Calls for Boxed Warnings for CAR T-Cell ImmunotherapiesFollowing an investigation that began in November 2023, the FDA now requires boxed warnings regarding T-cell malignancies on all BCMA- and CD19-directed T-cell products.
Latest:
Exploring PSMA Therapies in Prostate CancerDeclan Murphy, MD, discusses the current interest in using PSMA, following the FDA’s approval of Gallium 68 PSMA-11, which marks the first ever drug for PET imaging of PSMA-positive lesions in men with prostate cancer.
Latest:
Banerjee Discusses Emerging Research for CAR T in Multiple MyelomaRahul Banerjee, MD, discusses new frontiers in the treatment of multiple myeloma with CAR T-cell therapy.
Latest:
Gene Editing Used to Enhance AML Antigen Targeting for CAR T-Cell TherapySiddhartha Mukherjee, MD, discusses potential means of targeting chimeric antigen receptor T-cell therapy for patients with acute myeloid leukemia.
Latest:
CRX100 Delivers Responses and Tolerability in Platinum-Resistant Ovarian CancerEx vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.
Latest:
Overview of MET Amplification and MET Exon 14 Skipping Mutations in NSCLCGiuseppe Giaccone, MD, PhD, discusses alterations in the MET gene that can be oncogenic drivers in patients with non–small cell lung cancer.
Latest:
Familiarity Eases Tolerability Challenges With Newer ADCs in Breast CancerIn this feature, Targeted Oncology spoke to experts in breast cancer treatment on the trends in management of toxicity with the growing drug class of antibody-drug conjugates.
Latest:
Defining Advances in the WHO Classification for AMLThe required blast threshold of 20% has now been omitted from AML with defining genetic abnormalities with the exception of AML with BCR::ABL1 and AML with CEBPA mutation.
Latest:
Darolutamide Plus ADT, Docetaxel Improves OS in Patients with mHSPC, Regardless of Disease Volume and RiskThe triplet therapy should become the new standard of care for this patient population, according to recent data.
Latest:
How Will New Immunotherapies Fit Into the Treatment Landscape of Follicular Lymphoma?Future directions for follicular lymphoma treatments include potential use earlier in treatment or as combination therapy, identifying patients who will benefit most from treatment, and minimizing the costs of therapy while maximizing accessibility.
Latest:
Current and Emergent Therapies for Systemic MastocytosisThe field of mastocytosis is witnessing a paradigm shift with precision medicine in the form of mutant KIT inhibitors.
